| 2025-09-08 | Anti glaucoma drugs - Mechanism | 0:00 | 16 | |
|
| 2025-09-04 | Vitamin deficiency states | 0:00 | 14 | |
|
| 2025-08-14 | Cardiac biomarkers | 0:00 | 12 | |
|
| 2025-08-14 | Morphological changes in acute MI myocardial infarction | 0:00 | 12 | |
|
| 2025-08-14 | Hypertrophic cardiomyopathy | 0:00 | 12 | |
|
| 2025-08-14 | Modified dukes criteria - Infective endocarditis | 0:00 | 13 | |
|
| 2025-08-11 | Radiosensitive and radioresistant tumors | 0:00 | 1 | |
|
| 2025-08-11 | Radiosensitive and radioresistant tumors | 0:00 | 2 | |
|
| 2025-08-11 | Vasculitis - modified chapel hill classification | 0:00 | 2 | |
|
| 2025-08-11 | Vasculitis - modified chapel hill classification | 0:00 | 3 | |
|
| 2025-08-09 | Neurocutaneous syndromes - part 6 | 0:00 | 0 | |
|
| 2025-08-09 | Gallstones and types - part 4 | 0:00 | 0 | |
|
| 2025-08-09 | Neurocutaneous syndromes - part 5 | 0:00 | 0 | |
|
| 2025-08-09 | Gallstones and types - part 3 | 0:00 | 0 | |
|
| 2025-08-09 | Neurocutaneous syndromes - part 4 | 0:00 | 2 | |
|
| 2025-08-09 | Gallstones and types - part 2 | 0:00 | 0 | |
|
| 2025-08-09 | Neurocutaneous syndromes - part 3 | 0:00 | 1 | |
|
| 2025-08-09 | Gallstones and types | 0:00 | 0 | |
|
| 2025-08-09 | Neurocutaneous syndromes - part 2 | 0:00 | 1 | |
|
| 2025-08-08 | Acute hepatitis vs chronic hepatitis - part 2 | 0:00 | 0 | |
|
| 2025-08-08 | Neurocutaneous syndromes - part 1 | 0:00 | 0 | |
|
| 2025-08-08 | Acute hepatitis vs chronic hepatitis | 0:00 | 1 | |
|
| 2025-08-08 | Malignancies and translocations - part 2 | 0:00 | 0 | |
|
| 2025-08-08 | Tumour markers in testicular germ cell tumours | 0:00 | 0 | |
|
| 2025-08-08 | Malignancies and translocations - part 1 | 0:00 | 0 | |
|
| 2025-08-08 | Renal diseases and electron microscopy findings - part 2 | 0:00 | 0 | |
|
| 2025-08-08 | Multiple myeloma and cells - part 2 | 0:00 | 0 | |
|
| 2025-08-07 | Hemolytic anaemia classification - part 3 | 0:00 | 0 | |
|
| 2025-08-07 | Nephrotic vs nephritic syndrome - part 2 | 0:00 | 0 | |
|
| 2025-08-07 | Renal diseases and electron microscopy findings | 0:00 | 0 | |
|
| 2025-08-07 | Multiple myeloma and cells - part 1 | 0:00 | 0 | |
|
| 2025-08-07 | Lymphomas and chromosomal translocations | 0:00 | 1 | |
|
| 2025-08-07 | Nephrotic vs nephritic syndrome - part 4 | 0:00 | 1 | |
|
| 2025-08-07 | Nephrotic vs nephritic syndrome - part 3 | 0:00 | 0 | |
|
| 2025-08-05 | Nephrotic vs nephritic syndrome | 0:00 | 2 | |
|
| 2025-08-05 | Hemolytic anaemia classification - part 1 | 0:00 | 0 | |
|
| 2025-08-05 | Hemolytic anaemia classification - part 2 | 0:00 | 0 | |
|
| 2025-08-05 | Ischemic cardiac myocytes - time of onset | 0:00 | 2 | |
|
| 2025-08-05 | Acute myocardial infarction morphological changes - part 6 | 0:00 | 1 | |
|
| 2025-08-03 | Acute myocardial infarction morphological changes - part 5 | 0:00 | 5 | |
|
| 2025-08-03 | Hemostatic disorders and lab findings - part 2 | 0:00 | 4 | |
|
| 2025-07-29 | Acute myocardial infarction morphological changes - part 4 | 0:00 | 0 | |
|
| 2025-07-29 | Von Willebrand disease - part 2 | 0:00 | 1 | |
|
| 2025-07-29 | Acute myocardial infarction morphological changes - part 3 | 0:00 | 1 | |
|
| 2025-07-29 | Von Willebrand disease - part 1 | 0:00 | 1 | |
|
| 2025-07-29 | Acute myocardial infarction morphological changes - part 2 | 0:00 | 0 | |
|
| 2025-07-29 | Factors affecting iron absorption | 0:00 | 1 | |
|
| 2025-07-29 | Acute myocardial infarction morphological changes - part 1 | 0:00 | 1 | |
|
| 2025-07-29 | Haemostatic disorders and lab findings - part 1 | 0:00 | 6 | |
|
| 2025-07-28 | Burkitts lymphoma - part 3 | 0:00 | 1 | |
|
| 2025-07-27 | Anemia - morphological classification part 2 | 0:00 | 0 | |
|
| 2025-07-27 | Modified dukes criteria infective endocarditis 2023 - part 3 | 0:00 | 0 | |
|
| 2025-07-27 | Anemia - morphological classification part 1 | 0:00 | 0 | |
|
| 2025-07-27 | Modified dukes criteria infective endocarditis 2023 - part 2 | 0:00 | 0 | |
|
| 2025-07-26 | Stains in pathology | 0:00 | 0 | |
|
| 2025-07-26 | Modified dukes criteria infective endocarditis 2023 - part 1 | 0:00 | 0 | |
|
| 2025-07-26 | Tumor markers - part 3 | 0:00 | 0 | |
|
| 2025-07-26 | Radiosensitive and radioresistant tumors | 0:00 | 0 | |
|
| 2025-07-26 | Tumor markers - part 2 | 0:00 | 0 | |
|
| 2025-07-26 | Vasculitis - modified chapel hill classification part 2 | 0:00 | 1 | |
|
| 2025-07-26 | Tumor markers - part 1 | 0:00 | 0 | |
|
| 2025-07-26 | Vasculitis - modified chapel hill classification part 1 | 0:00 | 1 | |
|
| 2025-07-25 | Macrophages and site | 0:00 | 0 | |
|
| 2025-07-25 | Vasculitis and their sites - part 2 | 0:00 | 0 | |
|
| 2025-07-25 | Immune cell and associated antigens | 0:00 | 0 | |
|
| 2025-07-25 | Systematic lupus erythematosus SLE - characteristic findings part 2 | 0:00 | 1 | |
|
| 2025-07-25 | Vasculitis and their sites - part 1 | 0:00 | 0 | |
|
| 2025-07-25 | Histopathology named cells - part 2 | 0:00 | 0 | |
|
| 2025-07-24 | Type 2 antibody mediated hypersensitivity - part 3 | 0:00 | 0 | |
|
| 2025-07-24 | Non HLA genes associated with autoimmune diseases - part 2 | 0:00 | 2 | |
|
| 2025-07-24 | Type 2 antibody mediated hypersensitivity - part 1 | 0:00 | 0 | |
|
| 2025-07-24 | Systematic lupus erythematosus SLE - characteristic findings part 1 | 0:00 | 0 | |
|
| 2025-07-24 | Histopathology named cells - part 1 | 0:00 | 0 | |
|
| 2025-07-24 | Central nervous system tumours and their histopathological findings - part 3 | 0:00 | 0 | |
|
| 2025-07-24 | Central nervous system tumours and their histopathological findings - part 5 | 0:00 | 0 | |
|
| 2025-07-24 | Type 2 antibody mediated hypersensitivity - part 2 | 0:00 | 0 | |
|
| 2025-07-24 | Central nervous system tumours and their histopathological findings - part 4 | 0:00 | 0 | |
|
| 2025-07-23 | Central nervous system tumours and their histopathological findings - part 1 | 0:00 | 1 | |
|
| 2025-07-23 | Transplant rejection reactions - part 4 | 0:00 | 0 | |
|
| 2025-07-23 | Non HLA genes associated with autoimmune diseases - part 1 | 0:00 | 0 | |
|
| 2025-07-23 | Staining pattern and antigens - part 2 | 0:00 | 0 | |
|
| 2025-07-23 | Central nervous system tumours and their histopathological findings - part 2 | 0:00 | 0 | |
|
| 2025-07-22 | Neurocutaneous syndromes - part 6 | 0:00 | 1 | |
|
| 2025-07-21 | Pathological named bodies - part 4 | 0:00 | 0 | |
|
| 2025-07-21 | Malignancies and translocations - part 2 | 0:00 | 0 | |
|
| 2025-07-21 | Pathological named bodies - part 3 | 0:00 | 0 | |
|
| 2025-07-21 | Malignancies and translocations - part 1 | 0:00 | 0 | |
|
| 2025-07-21 | Pathological named bodies - part 2 | 0:00 | 0 | |
|
| 2025-07-20 | Neurocutaneous syndromes - part 1 | 0:00 | 1 | |
|
| 2025-07-20 | Pathological named bodies - part 1 | 0:00 | 5 | |
|
| 2025-07-20 | Multiple myeloma and cells - part 2 | 0:00 | 2 | |
|
| 2025-07-20 | Vacutainers - part 2 | 0:00 | 0 | |
|
| 2025-07-20 | Multiple myeloma and cells - part 1 | 0:00 | 0 | |
|
| 2025-07-20 | Vacutainers - part 1 | 0:00 | 0 | |
|
| 2025-07-19 | Lymphomas and chromosomal translocations | 0:00 | 1 | |
|
| 2025-07-18 | Mallory bodies versus councilman bodies - part 2 | 0:00 | 0 | |
|
| 2025-07-17 | Hemolytic anaemia classification - part 3 | 0:00 | 0 | |
|
| 2025-07-17 | Mallory bodies versus councilman bodies - part 1 | 0:00 | 1 | |
|
| 2025-07-17 | Hemolytic anaemia classification - part 1 | 0:00 | 2 | |
|
| 2025-07-17 | Hemostatic disorders and lab findings - part 2 | 0:00 | 0 | |
|
